An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: An overview of the oncorx project

Supportive Care in Cancer

Volumn 18, Issue 7, 2010, Pages 883-891

  Yap, Kevin Yi Lwern ^a   Kuo, En Yi ^a   Lee, Jonathan Jun Jie ^a   Chui, Wai Keung ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Anticancer drugs; Complementary and alternative medicines; Database; Drug interaction; Herbal medicines; Traditional Chinese medicines

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BUSULFAN; CAPECITABINE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ESTRAMUSTINE; FLUDARABINE; IFOSFAMIDE; IXABEPILONE; LOMUSTINE; MELPHALAN; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; THIOTEPA; TREOSULFAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ALOPECIA; ALTERNATIVE MEDICINE; ARTICLE; CHINESE MEDICINE; COMPUTER PROGRAM; DATA BASE; DRUG INTERACTION; FATIGUE; INFLAMMATION; NAUSEA; ONCOLOGY; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; VOMITING;

EID: 84984560516     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0729-9     Document Type: Article

References (45)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ, American Cancer Society (2007) Global cancer facts and figures 2007. Available via http://www.cancer.org/downloads/STT/Global-Facts-and-Figures-2007-rev2.pdf. Accessed 8 August 2009
2. Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/ alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4. doi:10.1186/1472-6874-7-4 (Pubitemid 46585636)
3. Bressler R (2005) Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 60:24-25 (Pubitemid 41318296)
4. Tascilar M, de Jong FA, Verweij J, Mathijssen RHJ (2006) Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 11:732-741. doi:10.1634/theoncologist.11-7-732 (Pubitemid 44157561)
5. Cassileth B, Heitzer M, Gubili J (2008) Integrative oncology: complementary therapies in cancer care. Cancer Chemother Rev 3:204-211
6. Oldendick R, Coker AL, Wieland D, Raymond JI, Probst JC, Schell BJ, Stoskopf CH (2000) Population-based survey of complementary and alternative medicine usage, patient satisfaction, and physician involvement. South Carolina Complementary Medicine Program Baseline Research Team. South Med J 93:375-381
7. Yap KY-L, Chui WK, Chan A (2008) Drug interactions between chemotherapeutic regimens and antiepileptics. ClinTher 30:1385-1407. doi:10.1016/j.clinthera.2008.08.011
8. Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489-2503. doi:10.1200/JCO.2004.08.182 (Pubitemid 41115408)
9. Kuhlmann J, Mück W (2001) Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 24:715-725. doi:0114-5916/01/0010-0715
10. Thomson Healthcare (2007) Micromedex® Healthcare Series [internet database]. Available via http://www.micromedex.com. Accessed 8 August 2009
11. Gerstner LV Jr (2008) Memorial Sloan-Kettering Cancer Center - cancer information (about herbs, botanicals and other products). Available via http://www.mskcc.org/mskcc/html/11570.cfm. Accessed 8 August 2009
12. Jellin JM, Gregory PJ (2007) Natural medicines comprehensive database, 10th edn. Therapeutic Research Faculty, Stockton, CA
13. Chang H-M, But PP-H, Yao S-C, Wang L-L, Yeung SC-S (2001) Pharmacology and applications ofChinese materia medica. World Scientific, Singapore
14. British Medical Association, Pharmaceutical Society of Great Britain (2007) British national formulary, 53rd edn. BMJ & RPS, London
15. Lacy CF, Armstrong LL, Goldman MP, Lance LL (2007-2008) Drug information handbook with international trade names index, 15th edn. Lexi-comp, Hudson, OH
16. Solimando DAJ (2007) Drug information handbook for oncology, 6th edn. Lexi-comp, Hudson, Ohio
17. e-MS Inc (2004) TCM Assistant. Available via http://www.tcmassistant.com/ index.html. Accessed 8 August 2009
18. Rootdown LLC (2008) Rootdown.us - grow together (v2.187.423.57). Available via http://www.rootdown.us/. Accessed 8 August 2009
19. Strain JJ, Caliendo G, Himelein C (1998) Using computer databases to predict and avoid drug-drug interactions in the cancer patient requiring psychotropics. Psychooncology 7:321-332
20. BC Cancer Agency (2007) BCCA cancer drug manual. Available via http://www.bccancer.bc.ca/HPI/DrugDatabase/default.htm. Accessed 8 August 2009
21. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J 1:167-170
22. Aetna InteliHealth Inc. Index of herbal medicines and supplements. Available via http://www.intelihealth.com/IH/ihtIH/WSIHW000/8513/31402.html. Accessed 8 August 2009
23. Thomson Healthcare (2007) Micromedex® Healthcare Series (version 5.1) [intranet database]. Available via http://www.thomsonhc.com/hcs/librarian/ PFPUI/fV1mNyY303TXxR. Accessed 8 August 2009
24. Drugsite Trust (2000) Drugs.com™ drug information online. Available via http://www.drugs.com. Accessed 8 August 2009
25. Gold Standard Inc. Caremark Drug Interactions. Available via http://cpref.gsm.com/inter.asp?r=8084. Accessed 8 August 2009
26. Enhanced Medical Decisions Inc (2007) DoublecheckMD. com™ Available via http://www.doublecheckmd.com. Accessed 8 August 2009
27. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT (2000) An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273-282
28. Sandoval M, Charbonnet RM, Okuhama NN, Roberts J, Krenova Z, Trentacosti AM, Miller MJ (2000) Cat's claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection. Free Radic Biol Med 29:71-78. doi:10.1016/S0891-5849(00)00327-0 (Pubitemid 30658139)
29. Seeff LB (2007) Herbal hepatotoxicity. Clin Liver Dis 11:577-596. doi: 10.1016/j.cld.2007.06.005 (Pubitemid 47302344)
30. Ludwig R, Weirich A, Abel U, Hofmann W, Graf N, Tournade M-F (1999) Hepatotoxicity in patients treated according to the Nephroblastoma Trial and Study SIOP-9/GPOH. Med Pediatr Oncol 33:462-469
31. Marinelli A, de Brauw LM, Beerman H, Keizer HJ, van Bockel JH, Tjaden UR, van de Velde CJH (1996) Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 26:341-350
32. Yarnell E, Abascal K (2007) Interaction of herbal constituents with cytochrome P450 enzymes. Altern Complement Ther 13:239-247. doi:10.1089/act. 2007.13508 (Pubitemid 350070343)
33. Unger M, Frank A (2004) Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 18:2273-2281. doi:10.1002/rcm.1621 (Pubitemid 39297365)
34. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276-287. doi:10.1067/mcp.2002.126913
35. Jones BD, Runikis AM (1987) Interaction of ginseng with phenelzine. J Clin Psychopharmacol 7:201-202
36. Shin HR, Kim JY, Yun TK, Morgan G, Vainio H (2000) The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control 11:565-576. doi:10.1023/A:1008980200583 (Pubitemid 30342846)
37. Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, Folan MM, Condifer KA (1999) Inhibition of caffeine metabolism by estrogen replacement therapy in postmen- opausal women. J Clin Pharmacol 39:936-940
38. American Society of Health-System Pharmacists (2007) AHFS drug information, 2007th edn. American Society of Health-System Pharmacists, Bethesda, MD
39. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349-356. doi:10.1046/j.1365-2125.2002.01683.x (Pubitemid 35334946)
40. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CYW, Cui YY, Venkataramanan R (2004) Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32:512-518
41. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J-S, Chavin KD (2003) Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290:1500-1504
42. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacop sychiatry 31:16-21. doi:10.1055/s-2007-979341
43. Mathijssen RHJ, Verweij J, De Bruijn P, De Jonge MJA, Sparreboom A (2002) Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients. Proc Am Assoc Cancer Res 43:492 (abstract 2443)
44. Shader RI, Greenblatt DJ (1988) Bees, ginseng and MAOIs revisited. J Clin Psychopharmacol 8:235
45. Parekh HS, Liu G, Wei MQ (2009) A new dawn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer 8:21